Literature DB >> 19887858

N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria.

Luca Filippi1, Elena Gozzini, Patrizio Fiorini, Sabrina Malvagia, Giancarlo la Marca, Maria Alice Donati.   

Abstract

In propionic aciduria and methylmalonic aciduria, hyperammonemia as a symptom of metabolic decompensation is one of the major clinical problems. Hyperammonemia is a true neonatal emergency with high mortality and neurological complications in most survivors. It requires a rapid and vigorous treatment in order to normalize the ammonia concentration as fast as possible. We report on two full-term neonates, one with propionic aciduria and the other with methylmalonic aciduria, whose plasma ammonia concentrations responded dramatically to oral N-carbamylglutamate. N-carbamylglutamate, added to the classic treatment, quickly normalized plasma ammonia levels in both patients and avoided the need of hemodialysis or peritoneal dialysis. A particularly sudden fall of ammonia was obtained in one patient through beginning N-carbamylglutamate treatment precociously. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19887858     DOI: 10.1159/000255168

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  25 in total

1.  Nutritional and Pharmacological Management during Chemotherapy in a Patient with Propionic Acidaemia and Rhabdomyosarcoma Botryoides.

Authors:  E Martín-Hernández; P Quijada-Fraile; L Oliveros-Leal; Mt García-Silva; C Pérez-Cerdá; M Baro-Fernández; V Pérez-Alonso; Jl Vivanco
Journal:  JIMD Rep       Date:  2012-03-21

2.  Short-term outcome of propionic aciduria treated at presentation with N-carbamylglutamate: a retrospective review of four patients.

Authors:  Sébastien Lévesque; Marie Lambert; Aspasia Karalis; Serge Melancon; Laura Russell; Nancy Braverman
Journal:  JIMD Rep       Date:  2011-09-06

3.  Stable isotopes in the diagnosis and treatment of inherited hyperammonemia.

Authors:  Nicholas Ah Mew; Marc Yudkoff; Mendel Tuchman
Journal:  J Pediatr Biochem       Date:  2014-01-01

4.  N-carbamylglutamate treatment for acute neonatal hyperammonemia in isovaleric acidemia.

Authors:  Cigdem Seher Kasapkara; Fatih Suheyl Ezgu; Ilyas Okur; Leyla Tumer; Gursel Biberoglu; Alev Hasanoglu
Journal:  Eur J Pediatr       Date:  2011-01-05       Impact factor: 3.183

5.  Precision medicine in rare disease: Mechanisms of disparate effects of N-carbamyl-l-glutamate on mutant CPS1 enzymes.

Authors:  Dashuang Shi; Gengxiang Zhao; Nicholas Ah Mew; Mendel Tuchman
Journal:  Mol Genet Metab       Date:  2016-12-08       Impact factor: 4.797

6.  N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia.

Authors:  Nicholas Ah Mew; Robert McCarter; Yevgeny Daikhin; Itzhak Nissim; Marc Yudkoff; Mendel Tuchman
Journal:  Pediatrics       Date:  2010-06-21       Impact factor: 7.124

7.  Cobalamin C defect presenting as severe neonatal hyperammonemia.

Authors:  Diego Martinelli; Andrea Dotta; Laura Massella; Stefano Picca; Alessandra Di Pede; Sara Boenzi; Chiara Aiello; Carlo Dionisi-Vici
Journal:  Eur J Pediatr       Date:  2010-12-10       Impact factor: 3.183

Review 8.  Hyperammonemia in review: pathophysiology, diagnosis, and treatment.

Authors:  Ari Auron; Patrick D Brophy
Journal:  Pediatr Nephrol       Date:  2011-03-23       Impact factor: 3.714

Review 9.  Methylmalonic and propionic acidemias: clinical management update.

Authors:  Jamie L Fraser; Charles P Venditti
Journal:  Curr Opin Pediatr       Date:  2016-12       Impact factor: 2.856

Review 10.  Liver transplantation in propionic and methylmalonic acidemia: A single center study with literature review.

Authors:  Nishitha R Pillai; Bridget M Stroup; Anna Poliner; Linda Rossetti; Brandy Rawls; Brian J Shayota; Claudia Soler-Alfonso; Hari Priya Tunuguntala; John Goss; William Craigen; Fernando Scaglia; V Reid Sutton; Ryan Wallace Himes; Lindsay C Burrage
Journal:  Mol Genet Metab       Date:  2019-11-07       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.